JPMorgan analyst Lisa Gill raised the firm’s price target on Privia Health (PRVA) to $32 from $29 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health price target raised to $24 from $23 at Barclays
- Privia Health Group Approves Key Proposals at Meeting
- Privia Health’s Earnings Call Highlights Growth and Challenges
- Privia Health Group’s Strong Performance and Strategic Expansion Drive Positive Outlook
- Privia Health Reports Strong Q1 2025 Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue